Overview of 'allergy and allergic diseases: With a view to the future'

British Medical Bulletin

Volumn 56, Issue 4, 2000, Pages 843-864

  Kay, A B ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; ATOPIC DERMATITIS; ATOPY; CLINICAL FEATURE; CYTOKINE PRODUCTION; IMMUNOTHERAPY; INFLAMMATION; PRICK TEST; PRIORITY JOURNAL; REVIEW; TH2 CELL; URTICARIA;

ADOLESCENT; ADULT; ALLERGENS; ANAPHYLAXIS; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIET; GLUCOCORTICOIDS; HUMANS; HYGIENE; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INFANT; MODELS, IMMUNOLOGICAL; PREVALENCE; RECEPTORS, IGE; RESEARCH; TH2 CELLS;

EID: 0034441697     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1258/0007142001903481     Document Type: Review

References (105)

1. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren
2. A national estimate of the economic costs of asthma
3. Allergie
4. The subclass of IgG antibody in allergic disease: II. The IgG subclass of antibodies produced following natural exposure to dust mite and grass pollen in atopic and non-atopic individuals
5. Human TH1 and TH2 subsets: Doubt no more
6. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients
7. IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression
8. Dermatophagoides pteronyssinus II-induced interleukin-4 and interferon-gamma expression by freshly isolated lymphocytes of atopic individuals
9. Human atopen-specific types 1 and 2 T helper cell clones
10. Messenger RNA expression of the cytokine gene cluster, IL-3, IL-4, IL-5 and GM-CSF in allergen-induced late-phase cutaneous reactions in atopic subjects
11. H2-type bronchoalveolar lavage T-lymphocyte population in atopic asthma
12. Cytokine messenger RNA expression for IL-3, IL4, IL-5 and GM-CSF in the nasal mucosa after local allergen provocation: Relationship to tissue eosinophilia
13. Transplacental priming of the human immune system to environmental allergens: Universal skewing of initial T cell responses towards the Th2 cytokine profile
14. The role of allergy in the development of asthma
15. Induction of Th1 and Th2 CD4+ T cell responses: The alternative approaches
16. Peptide dose, affinity and time of differentiation can contribute to the Th1/Th2 cytokine balance
17. Differences in the prevalence of asthma and atopic sensitisation between East and West Germany
18. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany
19. Give us this day our daily germs
20. Intestinal microflora of Estonian and Swedish infants
21. The intestinal microflora in allergic Estonian and Swedish 2-year-old children
22. Prevalence of hay fever and allergic sensitization in farmers children and their peers living in the same rural community
23. The alliance of genes and environment in asthma and allergy
24. Protective and harmful effects of viral infections in childhood on wheezing disorders and asthma
25. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood
26. Predictors of asthma and persistent wheeze in a national sample of children in the United States. Association with social class, perinatal events, and race
27. Risk factors for asthma in inner city children
28. The epidemic of allergy, and asthma
29. Peanut allergens
30. HLA-Dw2: A genetic marker for human immune response to short ragweed pollen allergen Ra 5. I. Response resulting primarily from natural antigenic exposure
31. A new variant of the β subunit of the high-affinity receptor for immunoglobulin E (FcεRI-β E237G): Association with measure of atopy and bronchial hyper-responsiveness
32. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations
33. Tumour necrosis factor haplotypes and asthma
34. A polymorphism in the 5′-flanking region of the CD14 gene is associated with circulating soluble CD14 levels with total serum IgE
35. 4 synthase promoter polymorphism and risk of aspirin-induced asthma
36. The high affinity IgE receptor (Fc-epsilon RI): From physiology to pathology
37. IgE-mediated allergen presentation via FcεRI on antigen-presenting cells
38. Blood eosinophils from atopic donors express mRNA for the α, β and γ subunits of the high affinity IgE receptor (FcεRI) and intracellular, but not cell surface, α subunit protein
39. Induction and regulation of the IgE response
40. IGIF does not drive Th1 development but synergizes with IL 12 for interferon-γ production and activates IRAK and NFκB
41. + T cells
42. Antigen presentation is enhanced by targeting antigen to the FcεRII by antigen-anti-FcεRII conjugates
43. CD23/IgE-mediated regulation of the specific antibody response in vivo
44. Drug therapy: Treatment of asthma with drugs modifying the leukotriene pathway
45. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and eotaxin-2 and MCP4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (MCP-3 and RANTES)
46. + T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in atopic asthmatics
47. Cytokine messenger RNA expression for IL-3, IL4, IL-5 and GM-CSF in the nasal mucosa after local allergen provocation: Relationship to tissue eosinophilia
48. Basophils, eosinophils and mast cells in atopic and non-atopic asthma and in late-phase allergic reactions in the lung and skin
49. Late cutaneous allergic responses in isolated IgE-dependent reactions
50. IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions
51. Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics
52. Interleukin-13: Central mediator of allergic asthma
53. Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects
54. Human eosinophils regulate human lung- and skin- derived fibroblast properties in vitro: A role for transforming growth factor beta (TGF-β)
55. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin-5: The role of specific adhesion molecules and phosphatidylinositol 3-kinase
56. Interleukin 5 regulates the isoform expression of its own receptor α-subunit
57. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6 and GM-CSE
58. Hemopoietic progenitors and cytokines in allergic inflammation
59. Nerve growth factor: An important molecule in allergic inflammation and tissue remodelling
60. The role of neurotrophins in allergic bronchial asthma
61. Neuropeptides
62. Sensory neuropeptides induce histamine release from bronchoalveolar lavage cells in both nonasthmatic coughers and cough variant asthmatics
63. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
64. Second generation antihistamines: A comparative review
65. Long-term clinical efficacy of grass-pollen immunotherapy
66. Immunologic changes associated with allergen immunotherapy
67. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy
68. Grass pollen immunotherapy decreases the number of mast cells in the skin
69. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
70. Role of interleukin 10 in specific immunotherapy
71. IL-10: Evolving concepts
72. Allergen isoforms for immunotherapy: Diversity, degeneracy and promiscuity
73. Viewpoint: The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than differences
74. Therapeutic strategies for allergic diseases
75. Synthetic glucocorticoids that dissociate transactivation and AP-1 transpression exhibit anti-inflammatory, activity in vivo
76. CD4 T-lymphocyte activation in acute severe asthma: Relationship to disease severity and atopic status
77. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma
78. Randomised, dose-ranging, placebo controlled study of a chimeric antibody to CD4 (keliximab) in chronic severe asthma
79. Clinical efficacy, of specific immunotherapy to cat dander: A double-blind placebo-controlled trial
80. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2
81. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
82. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis
83. Double-blind controlled trial of house dust mite allergen avoidance in atopic dermatitis
84. Recent therapeutic advances in dermatology
85. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria
86. Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies
87. Plasmapheresis for severe unremitting chronic urticaria
88. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy
89. Four recombinant isoforms of Cora I, the major allergen of hazel pollen, show different IgE-binding properties
90. Treatment of cat allergy with T-cell reactive peptides
91. HLA-DR restricted peptide candidates for bee venom immunotherapy
92. Gene vaccination: Plasmid DNA is more than just a blueprint
93. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization
94. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
95. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
96. Treatment of allergic asthma with monoclonal anti-IgE antibody
97. The effect of an anti-IgE monoclonal antibody on the early-and late-phase response to allergen inhalation in asthmatic subjects
98. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα
99. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial
100. Interleukin-4 and its receptor: Essential mediators of the allergic response
101. Effects of an antibody to interleukin-5 in a monkey model of asthma
102. Effects of an interleukin-5 blocking monodonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
103. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody
104. GATA transcription factor expression in T cells, monocytes and bronchial biopsies of normal and asthmatic subjects
105. Molecular identification of an IgE-dependent histamine-releasing factor